Media Events

Global markets look set to remain conflicted in 2024 with the consequences of historic rate hikes finally manifesting. What will the chain reactions be as rates, inflation, employment, growth, and geopolitics converge?

In our latest panel discussion portfolio manager Andy Acker, research analyst Agustin Mohedas, scientist Dr. Stephen Harrison and Akero's CEO Andrew Cheng, detailed the remarkable advances in disease categories that previously had limited treatment options, like NASH, a severe form of nonalcoholic fatty liver disease.

Accelerating innovation in the biotechnology sector may offer investors new potential growth opportunities. In a market environment where we believe investors should tread carefully, Jennifer Nichols, Client Portfolio Manager and Matthew Bullock, EMEA Head of Portfolio Construction and Strategy discussed how healthcare’s unique blend of defensive characteristics and growth potential may offer immunity from the downturn.